Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review

Meghana Kakarla 1, Musa Aussaja Gambo 2, Mustaфа Youssri Salama 1, Nathalie Haidar Ismail 1, Pardis Tavalla 1, Pulkita Uppal 1, Shaza A. Mohammed 1, Shriya Rajashekar 1, Suganya Giri Ravindran 1, Pousette Hamid 4

1. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 2. Pediatrics and Child Health, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 3. Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 4. Neurology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Meghana Kakarla, meghanaskakarla11@gmail.com

Abstract

The purpose of this study was to investigate the relationship between androgen deprivation therapy (ADT) and cardiovascular events in men with prostate cancer. Cardiovascular disease (CVD) is a primary cause of noncancer mortality in men with prostate cancer. Surveillance, Epidemiology, and End Results (SEER) Medicare-linked data revealed that CVD was responsible for about a quarter of deaths among men with prostate cancer, with a focus on the role of ADT as a contributing cause.

We performed a literature search in November 2021 utilizing search engines such as PubMed, Scopus, Science Direct, and Google Scholar. Original publications with data published between 2006 and 2020 were used in the investigation of men with prostate cancer undergoing ADT treatment with a CVD outcome. Two reviewers independently examined the content of the studies and extracted data from the final papers after they had been validated for quality using quality assessment tools.

A total of 14 observational studies and two randomized controlled trials are included in this systematic review. Sample sizes in the examined publications varied from 79 to 201,797 individuals. ADT was the intervention in all of the investigations. Seven of the included studies did not identify the type of ADT utilized; instead, they compared the outcomes of individuals who got ADT against those who did not. The specific type of ADT used is mentioned in the remaining nine studies included in the systematic review. Patients who got ADT, such as gonadotropin-releasing hormone (GnRH) agonist, combination androgen blockade, surgical castration, and oral anti-androgen, are compared to those who did not receive ADT to discover who had a better prognosis.

In conclusion, even though ADT has several negative metabolic side effects that increase the risk of cardiovascular toxicity, published research utilizing a variety of designs has demonstrated inconsistency in the impact of ADT on cardiovascular outcomes. While the risk of CVD should be considered when prescribing ADT, the findings suggest that it should not be considered a contraindication if the expected benefit is substantial.

Introduction And Background

In developed countries where there are large populations of older men, prostate cancer becomes a serious public health problem as its prevalence increases throughout life. In the United States, following lung cancer, prostate cancer is the second-highest cause of cancer death in males, with one estimate claiming that 1.3 million newly diagnosed cases of prostate cancer were recorded in men in 2018 associated with 285,358 deaths [1].

Since the first observation by Huggins and Hodges in 1941, it has been established that androgens (chiefly testosterone) play a key role in promoting tumor growth in prostate cancer patients [2]. Hence, effective anti-cancer therapy revolves around declining exposure to androgens and is referred to as androgen deprivation therapy (ADT). ADT is frequently used with localized treatments such as external beam radiotherapy or brachytherapy [3]. Even though orchectomy (surgical castration) is a simple and cheap procedure, it is less common due to its irreversibility [4]. Multiple strategies are employed to reduce exposure to testosterone including surgically removing the testes that produce 90% of the hormone or undergoing hormonal therapy which entails either reducing testosterone secretion or blocking androgen
receptors. Figure 1 depicts the hypothalamic-pituitary-gonadal axis and the sites of action of ADT.

![Diagram of hypothalamic-pituitary-gonadal axis and sites of action of ADT](image)

**FIGURE 1:** The hypothalamic-pituitary-gonadal axis and sites of action of androgen deprivation therapy.

GnRH: gonadotropin-releasing hormone; LH: luteinizing hormone; DHT: dihydrotestosterone; AR: androgen receptor

Created by the authors using biorender.com.

ADT has become more common in prostate cancer patients in recent years with approximately 40% of men undergoing ADT within six months of diagnosis [5]. Cooperberg and colleagues documented the significant increase in the use of ADT from 1989 to 2001 in their report. The most dramatic change was the increase in the use of ADT in external beam radiation therapy (RT) from 9.8% to 74.6% of patients [6].

The use of ADT in prostate cancer treatment has expanded beyond symptomatic metastatic disease treatment to include asymptomatic metastatic disease, primary treatment in localized disease when men are unable to undergo surgery or radiotherapy, adjunct therapy in high-risk diseases treated with radiotherapy, and salvage therapy after relapse after surgery or radiotherapy for presumed localized disease [7,8]. The European Association of Urology (EAU) guidelines recommend ADT for patients with metastatic disease (level of evidence: A) or combined with RT for individuals with high-risk cancers (level of evidence: A). Further, ADT can be used as a single treatment for men with advanced prostate cancer who refuse, are incapable to take any other form of local treatment, or are asymptomatic, with a prostate-specific antigen (PSA) higher than 50 ng/mL and a tumor that is not well-differentiated (level of evidence: A) [9].

A profound testosterone deficiency created by ADT can cause various adverse short and long-term health effects, including hot flushes, sexual dysfunction, obesity, sarcopenia, dyslipidemia, hyperinsulinemia, osteoporosis, type 2 diabetes mellitus (DM), and cardiovascular disease (CVD) [5,7,8]. Despite the fact that male sex is a known risk factor for coronary artery disease (CAD), evidence is mounting that testosterone may protect men with prostate cancer and men in general against heart disease [8]. ADT has been shown to promote adiposity in males; one study reported that after one year of ADT, body fat increased by 9.4% [10].

Most patients with prostate cancer have CVD as comorbidity [11-13]. In men with prostate cancer, CVD is the leading cause of non-cancer mortality. In the mid-1990s, Surveillance, Epidemiology and End Result (SEER) Medicare-linked data showed that CVD was responsible for around one-fourth of deaths among men with prostate cancer [14]. This piqued the researchers’ interest in determining what might be causing CVD in this group, focusing on the role of ADT as a contributory factor. In 2010, the American Heart Association, the American Society for Radiation Oncology, and the American Urological Association issued a joint statement to raise awareness of the ADT-CVD relationship [15].
In males with prostate cancer, significant increases in total blood cholesterol and triglyceride levels have also been related to androgen deficiency [16]. CAD is exacerbated by obesity and hyperlipidemia, both of which are risk factors [16]. ADT also raises hemoglobin A1C levels in men who already have DM [17]. Although more research is needed to demonstrate that the link between CVD and ADT is not due to confounding factors, there are multiple physiologically possible mechanisms through which ADT may contribute to CVD development [17].

Dyslipidemia, DM, and obesity are all well-known possible causes of atherosclerotic CVD [18]. Androgens may influence the local inflammatory response, which plays a critical role in the formation of atherosclerotic plaques, as well as plaque instability and rupture, via androgen receptor (AR)-dependent and AR-independent pathways, according to recent studies [17]. As a result, these consequences of medically induced hypogonadism may provide a mechanism through which ADT may raise the risk of cardiac morbidity and mortality. Hence, a thorough systematic review of published papers was performed to precisely analyze the relationship of ADT with cardiovascular events in prostate cancer patients and to assist healthcare providers in making related clinical decisions [10].

**Review**

**Methodology**

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards were used to perform this systematic review [19].

**Database and Search Strategy**

The research was started on November 20, 2021, using online libraries as our database. We searched PubMed, Scopus, Science Direct, and Google Scholar for data collection. Our keywords and medical subject heading (MeSH) search strategies used are depicted in Table 1.

| Database  | Search strategies                                                                                                                                                                                                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PubMed    | “Prostatic Neoplasms/drug therapy”[Majr] OR “Prostatic Neoplasms/therapy”[Majr] AND “Antineoplastic Agents, Hormonal”[Mesh] AND “Cardiovascular Diseases”[Mesh] AND (androgen deprivation therapy)   |
| Science Direct | Androgen deprivation therapy OR hormonal antineoplastic therapy AND prostate neoplasm AND cardiovascular effects                                                                                           |
| Google Scholar | Cardiovascular effects of androgen deprivation therapy in prostate cancer                                                                                                                                       |
| Scopus    | Prostate AND neoplasm AND androgen AND deprivation AND therapy AND cardiovascular AND effects                                                                                                                |

**TABLE 1: Keywords and medical subject heading search strategies used in the review.**

**Eligibility Criteria**

Studies investigating the association of ADT with cardiovascular events in prostate cancer patients were included without geographic location or publication status restrictions. The following selection criteria were included: (1) the study was published as an original article and contained the original data (excluding reviews, editorials, and conference summaries); (2) only included patients diagnosed with prostate cancer; (3) the intervention group included ADT (medical or surgical ADT); (4) studies with cardiovascular outcomes as the endpoint. Studies were excluded if any of the following factors were identified: (1) secondary studies; (2) laboratory studies; (3) animal studies; (4) database duplication and lack of detailed results.

**Quality Assessment Tools**

The assessment was separately conducted by two independent reviewers using the Cochrane risk bias assessment tool for clinical trials and the modified version of the Newcastle-Ottawa Scale (NOS) for quality assessment of observational studies [19]. With the help of another field expert, all discrepancies regarding the inclusion of the studies were resolved. High-quality studies were defined as those that received 70% or more of the highest number of stars. We excluded studies that were of low quality. In total, 16 studies were included [4,19-33]. Table 2 shows the quality assessment of clinical trials using the Cochrane Risk of Bias Tool.
### TABLE 2: Cochrane Risk of Bias Tool.

Table 3 shows the quality assessment of cohort studies using the modified version of the NOS.

| Citation                  | Random sequence generation | Allocation concealment | Selective reporting | Blinding (participants and personnel) | Blinding (outcome assessment) | Incomplete outcome data |
|---------------------------|-----------------------------|------------------------|---------------------|---------------------------------------|-------------------------------|-------------------------|
| D'Amico et al. [19]      | L                           | L                      | L                   | L                                     | L                             | L                       |
| Efstathiou et al. [20]   | L                           | L                      | L                   | L                                     | L                             | L                       |

%  
100 100 100 100 100 100

### TABLE 3: Modified version of the Newcastle-Ottawa Scale: cohort studies.

Table 3 shows the quality assessment of cross-sectional studies using the modified version of the NOS.

| Author                  | Year | Selection (maximum of four stars) | Comparability (maximum of two stars) | Outcome (maximum of three stars) | Total score (Maximum of nine stars) |
|-------------------------|------|-----------------------------------|--------------------------------------|-------------------------------|-------------------------------------|
| Keating et al. [23]     | 2006 | *                                 | *                                    | *                             | 9                                   |
| Seigal et al. [29]      | 2007 | *                                 | *                                    | *                             | 8                                   |
| Keating et al. [24]     | 2010 | *                                 | *                                    | *                             | 9                                   |
| Van Hommelrijk et al. [31] | 2010 | *                                 | *                                    | *                             | 8                                   |
| Kim et al. [29]         | 2011 | *                                 | *                                    | *                             | 8                                   |
| Hu et al. [20]          | 2012 | *                                 | *                                    | *                             | 9                                   |
| O'Farrell et al. [27]   | 2015 | *                                 | *                                    | *                             | 9                                   |
| Tech et al. [29]        | 2015 | *                                 | *                                    | *                             | 9                                   |
| Morgia et al. [26]      | 2016 | *                                 | *                                    | *                             | 9                                   |
| Oka et al. [28]         | 2016 | *                                 | *                                    | *                             | 9                                   |
| Nguyen et al. [33]      | 2018 | *                                 | *                                    | *                             | 8                                   |
| Wu et al. [4]           | 2020 | *                                 | *                                    | *                             | 9                                   |
| Author                  | Year | Selection (maximum of five stars) | Comparability (maximum of two stars) | Outcome (maximum of three stars) | Total score (maximum of 10 stars) |
|------------------------|------|-----------------------------------|--------------------------------------|----------------------------------|----------------------------------|
| Cleffi et al. [18]     | 2011 | *                                 | -                                    | **                               | 8                                |
| Gandaglia et al. [21]  | 2014 | *                                 | *                                    | **                               | 9                                |

**TABLE 4: Modified version of the Newcastle-Ottawa Scale: cross-sectional studies.**

**Selection and Data Extraction**

Two reviewers separately obtained data utilizing a predefined data extraction form from the final articles after quality assessment. With the help of a third reviewer, disagreements were addressed via debate or consensus. The following information was obtained: first author’s name, sample size, research features (i.e., year, design, and setting), type of ADT intervention used in the study, cardiovascular events described in every paper, and other non-cardiovascular events described in the study. Extracted data are summarized in Table 5.
| Authors         | Country     | Year | Study Type           | Data Source                                                                 | Sample Size | ADT Type                                                                 | Comorbidities                                                                 |
|----------------|-------------|------|----------------------|----------------------------------------------------------------------------|-------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Kim et al.     | Canada      | 2011 | Retrospective cohort | Provincial pharmacy and radiotherapy databases were linked to the provincial cancer registry | 5,948       | Not specified                                                             | Cardiovascular mortality, Other causes of mortality                           |
| Hu et al.      | United States | 2012 | Retrospective cohort | The US National Cancer Institute Surveillance Epidemiology and End Results (SEER) Medicare data for analyses, a linkage of population-based tumor registry data that currently covers areas representing 28% of the US population with Medicare administrative data | 182,757     | GnRH agonist                                                             | Peripheral arterial disease, venous thromboembolism                           |
| Gandaglia et al. | United States | 2014 | Retrospective cohort | Surveillance, Epidemiology, and End Results (SEER), eight Medicare-linked database | 40,474      | GnRH agonists, bilateral orchiectomy                                       | Coronary artery disease, myocardial infarction, sudden cardiac death          |
| O'Farrell et al. | Sweden      | 2015 | Retrospective cohort | Using data on filled drug prescriptions in Swedish national health care registers | 41,362      | Anti-androgens, gonadotropin-releasing hormone agonists underwent surgical orchiectomy | Cardiovascular risk, None                                                    |
| Teoh et al.    | China       | 2015 | Prospective cohort   | All Chinese prostate cancer patients from 2000 to 2009                          | 684         | Surgical castration, GnRH agonists                                        | Cardiovascular thrombotic risk, myocardial infarction, ischemic stroke       |
| Morgia et al.  | Italy       | 2016 | Cross-sectional study | Patients from 30 Italian institutes, including nine radiotherapy and 21 urology centers | 1,386       | GnRH agonist, orchiectomy, combined androgen blockade, oral anti-androgen | Cardiovascular prevalence, Osteoporosis                                      |
| Oka et al.     | Japan       | 2016 | Prospective observational study | Patients were at Toho University Sakura Medical Center | 58          | Not specified                                                             | Arterial stiffness, Hyperlipidemia                                            |
| Nguyen et al.  | United States | 2018 | Retrospective cohort | National Cancer Institutes Surveillance, Epidemiology, and End Results (SEER) Program Medicare-linked database | 201,797     | Not specified                                                             | Coronary artery disease, myocardial infarction, Bone fractures, diabetes, dementia, sexual dysfunction |
| Wu et al.      | Taiwan      | 2020 | Retrospective cohort | Data from patients were retrospectively collected from the Longitudinal Health Insurance Database of Taiwan | 10,843      | Not specified                                                             | Hypertension                                                                  |

**TABLE 5: Data extraction table.**

ADT: androgen deprivation therapy; GnRH: gonadotropin-releasing hormone

---

**Results**

**Literature Search**

Our extensive search resulted in 425 studies. Only 287 studies remained after removing 108 duplicates. In total, 264 articles were omitted after reviewing the abstracts and titles because they did not fit the inclusion criteria for the following causes: secondary studies, laboratory searches, and non-relevant topics. Finally, the entire paper was carefully read, of which five were further excluded because of non-cardiovascular endpoint. Figure 2 shows the PRISMA flowchart demonstrating the search process and study selection.
Study Characteristics

In total, 14 observational studies and two randomized control trials (RCTs) were included in the systematic review [4,19-33]. The key characteristics of the investigations (published between 2006 and 2020) that were considered are listed in Table 5. Seven studies were performed in America, one in Japan, two in Sweden, one in China, two in Canada, one in Taiwan, and one in Brazil. One clinical trial was done in the United States, Australia, and Canada. The sample sizes in the reviewed clinical investigations ranged from 79 to 201,797 participants. All studies had ADT as the intervention.

Seven of these studies did not mention the specific ADT type used and compared outcomes between patient groups that used ADT to those that did not. The other studies mention the specific type of ADT used and compared the outcomes between patient groups receiving different types of ADT such as GnRH agonists, combined androgen blockade (CAB), surgical castration, and oral anti-androgen with each other and with the patient group that did not receive ADT.

**ADT Versus Non-ADT Groups on Cardiovascular Events**

Myocardial infarction (MI), sudden cardiac death (SCD), and CAD: According to a study by Wallis et al., radiation (adjusted hazard ratios (aHR) = 1.16-1.28, $p < 0.0001-0.04$) and ADT (aHR = 1.18-1.32, $p < 0.0001$) were both linked with an elevated risk of CAD, SCD, and fracture requiring hospitalization after adjusting for baseline differences [32]. Radiotherapy was associated with a greater risk of MI (aHR = 1.20, $p = 0.02$) but not ADT ($p = 0.5$) [32]. In a study by Nguyen et al., individuals who used ADT had a greater risk of CAD (HR = 1.12, 95% confidence interval (CI) = 1.09-1.14) and acute MI (HR = 1.11, 95% CI = 1.08-1.15) than those who did not [33].

Standardized incidence ratio (SIR) of CVD, arrhythmia, and ischemic heart disease (IHD): Van Hemelrijck et al. reported that regardless of the history of cardiovascular illness, SIR for CVD was high in all males undergoing ADT, with the greatest values among those on endocrine treatment [31]. In this study, endocrine treatment was grouped into anti-androgens, estrogens, orchiectomy, GnRH agonists, GnRH agonist...
Arterial stiffness: Within six months following ADT, the entire sample exhibited no significant increase in arterial stiffness, according to Oka et al., although 55.2% of patients had an elevated cardio-ankle vascular index (CAVII) [28]. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels in the blood significantly increased one month after starting ADT and remained high thereafter.

Hypertension: Over a five-year follow-up period, Wu et al. found that the incidence of new-onset hypertension was 22.6 per 1,000 person-years in patients who did not receive ADT and 33.0 per 1,000 person-years in those who did receive ADT [4]. There was a 1.78-fold enhanced risk of developing new-onset hypertension in the group that received ADT than in the control group (95% CI = 1.61-1.96; p < 0.001). Furthermore, the CAB group had almost doubled the likelihood of subsequent hypertension (aHR = 1.93; 95% CI = 1.71-2.18; p < 0.001).

Cardiovascular morbidity: According to Saigal et al., patients with prostate cancer who had ADT for at least one year had a 20% greater risk of substantial cardiovascular morbidity than those who did not [29]. The individuals began to encounter this elevated risk after just 12 months of treatment.

Cardiovascular mortality: According to Kim et al., patients with no ADT, six months of ADT, and more than six months of ADT, respectively, had cumulative cardiovascular mortality of 2.6% (95% CI = 1.9-3.5%), 2.1% (95% CI = 1.2-5.5%), and 1.4% (95% CI = 1.0-2.0%) at seven years (Gray's p = 0.002) [25]. In this study, compared to the more than six-month ADT group, the non-ADT group had greater cardiovascular disease and risk factors at the start.

GnRH Agonist Versus Surgical Castration Versus CAB Versus Anti-androgens on Cardiovascular Events

General risk of CVD: According to a study by O'Farrell et al., males who used GnRH agonists (HR = 1.21, 95% CI = 1.18-1.25) had a greater risk of CVD than the orchietomy group (HR = 1.16; 95% CI = 1.08-1.25) and that of the anti-androgen group (HR = 0.87; 95% CI = 0.82-0.91) [27]. CVD risk was higher in males who had two or more cardiovascular incidents before starting ADT, with HR of CVD with GnRH agonist treatment of 1.91 (95% CI = 1.66-2.20), HR of CVD with anti-androgen therapy of 1.60 (95% CI = 1.24-2.06), and HR of CVD with orchietomy of 1.79 (95% CI = 1.61-2.76) versus comparison cohort. Teoh et al., according to the Kaplan-Meier analysis, determined that the orchietomy group had a higher incidence of new cardiovascular thrombotic events than the GnRH agonist group (p = 0.014) [30]. Age (HR = 1.072, 95% CI = 1.04-1.11; p = 0.001), hyperlipidemia (HR = 2.455, 95% CI = 1.53-3.95; p = 0.001), and orchietomy (HR = 1.648, 95% CI = 1.05-2.59; p = 0.031) were all found to be significant risk factors for cardiovascular thrombotic events according to multivariate Cox regression analysis.

CVD prevalence: In a study by Morgia et al., a total of 1,075 people were included, with 285 (26.51%) and 790 (75.49%) being discordant and concordant, respectively, according to the EAU criteria [26]. Discordant ADT was linked to a higher incidence of cardiovascular issues (odds ratio (OR) = 2.07; p = 0.01) in a multivariate logistic regression analysis adjusted for confounding factors, with GnRH agonists (HR = 3.95, 95% CI = 1.01-15.34; p = 0.005) and CAB (HR = 3.37, 95% CI = 1.10-10.30; p = 0.005) both contributing to cardiovascular complications.

CAD, MI, and SCD: According to Keating et al., treatment with GnRH agonists was linked to statistically significantly greater risks of incident CAD (aHR = 1.19, 95% CI = 1.10-1.28), MI (aHR = 1.28, 95% CI = 1.08-1.5) [23,24]. Oral anti-androgen monotherapy was not linked to any of the outcomes investigated. According to Gandaglia et al., overall, the rates of CAD, MI, and SCD were 25.9%, 15.6%, and 15.8%, respectively after 10 years [21]. After stratification by ADT status (ADT-naive vs. GnRH agonists vs. bilateral orchidectomy), the CAD rates were 25.1%, 26.9%, and 25.2%, respectively. The acute MI rates were 14.8%, 16.6%, and 14.8%, while the SCD rates were 14.2%, 17.7%, and 16.4%, respectively. GnRH agonists (all p = 0.001) but not bilateral orchidectomy (all p = 0.7) were linked to a greater risk of CAD, MI, and SCD in competing-risk multivariable regression models. According to Amico et al., males aged 65 and older who got six months of ADT had shorter delays to fatal MIs than men in this age group who did not get ADT (p = 0.017) or men younger than 65 years (p = 0.016) [19]. The time to fatal MIs in males aged 65 and older who got six to eight months of ADT compared to three months of ADT revealed no significant difference (p = 0.97). Here, ADT used was GnRH agonists.

Peripheral arterial disease (PAD) and venous thromboembolism (VTE): GnRH agonist usage was linked to a greater risk of PAD (aHR = 1.16; 95% CI = 1.12-1.21) and VTE (aHR = 1.10; 95% CI = 1.04-1.15). Orchiectomy was also linked to an elevated risk of PAD (aHR = 1.13; 95% CI = 1.02-1.26) and VTE (aHR = 1.27; 95% CI = 1.11-1.45), according to Hu and colleagues [22].
Cardiovascular mortality: According to Efstathiou et al., cardiovascular mortality was 5.9% for men getting longer-term adjuvant goserelin versus 4.8% for men receiving short-term goserelin after five years (Gray’s p = 0.16). In multivariate analyses, the treatment arm was not linked to an enhanced risk of cardiovascular mortality when censoring at the time of salvage goserelin (aHR = 1.02, 95% CI = 0.73–1.45; p = 0.9) [20]. Traditional cardiac risk variables such as age, CVD, and DM were all linked to a greater risk of CVD [20].

Discussion
Systematic reviews are considered the highest level of evidence and are typically emphasized in evidence-based practice because they reduce the errors and biases that can be introduced by single research. A well-conducted systematic review can assist researchers in objectively establishing the boundaries of what is known and what is unknown by summarizing all of the relevant and reliable evidence to enhance clinical decision-making [34,35]. This review attempted to involve all potentially relevant literature related to the research topic, which was cardiovascular events due to ADT in prostate cancer patients.

ADT may be beneficial to prostate cancer patients as part of curative treatment or as a palliative treatment for advanced disease. As the average life expectancy for males with prostate cancer increases, more people may be exposed to the possible adverse effects of ADT over longer periods. Care for cardiovascular events is an important element of the survivorship phase for a significant number of prostate cancer patients.

The 16 articles considered in the review were good quality studies as per the NOS and Cochrane risk bias assessment tools, out of which 14 were observational studies and two RCTs. Seven of these studies did not mention the specific ADT type used and compared outcomes between patient groups that use ADT to those that did not. The other studies mentioned the specific type of ADT used and compared the outcomes between patient groups receiving different types of ADT such as GnRH agonists, CAB, surgical castration, and oral anti-androgen with each other and with the patient group that did not receive ADT.

ADT Versus Non-ADT Groups on Cardiovascular Events

According to Wallis et al., there is an increase in CAD and SCD in both the groups individually but there is an increase in MI only in the non-ADT group [32]. When discussing the risks and benefits of treatment for localized prostate cancer for formulating a survivorship plan, the increased use of ADT for males with localized disease undergoing radiotherapy, and the observed higher prevalence of CAD, MI, and SCD in these patients should be considered. Nguyen et al. conducted a study that found males who received ADT had a higher incidence of CAD, MI, and SCD who did not receive ADT [33].

According to Van Hemelrijck et al., all prostate cancer patients, especially those treated with ADT, have enhanced relative risks of fatal and non-fatal CVD (SIR of CVD, arrhythmia, IHD) [51]. According to Oka et al., while the entire cohort did not show a significant change in arterial stiffness with ADT, some patients with CAVI showed an increase in arterial stiffness [28]. The ratio of LDL-C to HDL-C, or LDL-C/HDL-C may impact the development of arterial stiffness following ADT administration. Thus, doctors may be able to use LDL-C/HDL-C values to monitor prostate cancer patients who are at high risk of developing arterial stiffness following ADT therapy in prostate cancer patients.

According to the findings of Wu et al., males who had ADT for prostate cancer are at risk of having hypertension in the future [4]. According to Saigal et al., ADT is related to a significantly higher cardiovascular morbidity in prostate cancer patients and may reduce overall survival in low-risk men [29]. These findings are especially important for deciding whether or not to use ADT in prostate cancer patients in situations where the benefit has not been proven. According to Kim et al., individuals who received longer durations of ADT had a lower cardiovascular mortality rate than those who did not get ADT [25]. These discrepancies are most likely because of patient selection for ADT rather than the impact of ADT.

GnRH Agonist Versus Surgical Castration Versus CAB Versus Anti-androgens on Cardiovascular Events

According to Morgia et al., almost one-third of prostate cancer patients got inappropriate GnRH agonists who in turn had a higher prevalence of CVD [27]. Cardiovascular risk is significantly increased in males who received ADT in the form of GnRH agonists and surgical castration. However, prostate cancer patients who took anti-androgen had a lower chance of developing CVD risk factors. According to the findings of O’Farrell et al., there should be a strong indication for ADT in males with prostate cancer such that the benefits outweigh the risks; this is especially important in males with a recent history of CVD [28]. When compared to GnRH agonists, Teoh et al. claim that surgical castration is linked to a greater risk of cardiovascular thrombotic events. This is an essential factor to consider when choosing an ADT approach, particularly in older men with a history of hyperlipidemia [30].

GnRH agonist treatment for males with locoregional prostate cancer was linked to an elevated risk of diabetes and cardiovascular disease (CAD, MI, and SCD), according to Keating et al. (2006) [23]. ADT with GnRH agonists was linked to an elevated risk of diabetes and CVD (CAD, MI, and SCD). ADT with CAB was linked to an enhanced risk of CAD, ADT with orchietomy was linked to CAD and MI, and oral anti-androgen
monotherapy was not linked to any of the outcomes studied, according to Keating (2010) [24]. In males with non-metastatic prostate cancer, Gandaglia et al. revealed that the administration of GnRH agonists, but not orchidectomy, is still associated with a considerably higher risk of CAD, MI, and, especially SCD. In men with a higher risk of CVD, alternative types of ADT should be evaluated [22]. Amico et al. discovered that GnRH agonist use is linked to an earlier onset of fatal MIs in males 65 and older who are treated for six months versus males who are not treated with GnRH agonist [19].

Hu et al. state that ADT in the forms of GnRH agonists and surgical castration for non-metastatic prostate cancer is linked to an enhanced risk of PAD and VTE. The observational research design has limitations as does the inability to examine the usage of oral anti-androgens [22]. According to Efstathiou et al., a longer duration of adjuvant GnRH agonist medication does not improve cardiovascular mortality in males with locally advanced prostate cancer, whereas traditional cardiac risk factors, such as DM, prevalent CVD, and age, were significantly associated with higher cardiovascular mortality [20].

Conclusions

Although ADT has several negative metabolic side effects that increase the likelihood of cardiovascular toxicity, published studies utilizing various designs have discovered inconsistencies in the impact of ADT on cardiovascular outcomes. In those who use ADT, the incidence of cardiovascular events such as MI, SCD, CAD, hypertension, and overall cardiovascular morbidity is higher than in those who do not. GnRH agonists, when compared to other types of ADT, have a higher incidence of cardiovascular events such as MI, SCD, CAD, PAD, and VTE. ADT, on the other hand, does not increase cardiovascular mortality in men with locally advanced prostate cancer. The findings suggest that while CVD risk should be considered when prescribing ADT, it must not be considered a contraindication if the expected benefit is significant. Systematic reviews can help, but they can never take the place of excellent clinical reasoning. Availability of time and resources, experience, and compliance should all be considered when tailoring treatment to unique individuals and situations.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322/caac.21492
2. Huggins C, Hodges CV: Studies on prostate cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972, 22:232-40. 10.3322/canjclin.22.4.232
3. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Mosleh I: Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016, 133:537-41. 10.1161/CIRCULATIONAHA.115.012519
4. Wu YH, Jhan JH, Ke HL, et al.: Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score–matched longitudinal cohort study. Int J Clin Pharm. 2020, 42:1433-9. 10.1007/s11096-020-01143-9
5. Shahinian VB, Kuo YF, Freeman JL, Orlinuela E, Goodwin JS: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005, 103:1615-24. 10.1002/cncr.20955
6. Cooperberg MR, Hirotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H: Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009, 27:4506-15. 10.1200/JCO.2008.21.5229
7. Allan CA, Collins VR, Frydenberg M, McLachlan RJ, Matthiessen KL: Androgen deprivation therapy complications. Endocr Relat Cancer. 2014, 21:T119-29. 10.1530/ERC-13-0467
8. Smith MR, Finkelstein JS, McGovern FI, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002, 87:599-605. 10.1210/jcem.87.8.2829
9. Heidenreich A, Bastian PJ, Bellmunt J, et al.: EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014, 65:467-79. 10.1016/j.eururo.2013.11.002
10. Iaccovelli R, Ciccarese C, Bria E, et al.: The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018, 16:e645-53. 10.1016/j.clgc.2017.12.007
11. Gupta K, Elkon I, El-Bahesh E, Aragon-Ching JB: The utility of chemotherapy in the treatment of metastatic prostate cancer. Anticancer Agents Med Chem. 2016, 16:1166-71. 10.2174/1871520616666160121115558
12. Lu-Yao G, Stukel TA, Yao SL: Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004, 171:2285-90. 10.1097/01.ju.0000127740.96006.1a

13. Levine GN, D’Amico AV, Berger F, et al.: Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010, 121:833-40. 10.1161/CIRCULATIONAHA.109.192695

14. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS: Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990, 39:1314-9. 10.1016/0026-0495(90)90190-n

15. Nilsson PM, Nilsson JA, Berglund G: Population-attributable risk of coronary heart disease risk factors during long-term follow-up: the Malmö Preventive Project. J Intern Med. 2006, 260:134-41. 10.1111/j.1365-2796.2006.01671.x

16. Zareba P, Duivenvoorden W, Leong DP, Pinthus JH: Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?. Ther Adv Urol. 2016, 8:118-29. 10.17771/1756287215617872

17. Cheff I, Neto AS, Reis LO, et al.: [Androgen deprivation therapy and morbidity obesity: do they share cardiovascular risk through metabolic syndrome?]. Actas Urol Esp. 2011, 35:259-65. 10.1016/j.acer.2011.01.011

18. D’Amico AV, Denham JW, Crook J, et al.: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007, 25:2420-5. 10.1200/JCO.2006.09.3369

19. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89. 10.1186/s13643-021-01062-4

20. Elfstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandifer HM, Smith MR: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009, 27:92-9. 10.1200/JCO.2007.12.5752

21. Gandaglia G, Sun M, Popa I, et al.: The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int. 2014, 114:E32-9. 10.1111/bju.12752

22. Hu JC, Williams SB, O’Malley AJ, Smith MR, Nguyen PL, Keating NL.: Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012, 61:1119-28. 10.1016/j.eururo.2012.01.045

23. Keating NL, O’Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006, 24:4448-56. 10.1200/JCO.2006.06.2497

24. Keating NL, O’Malley AJ, Freedland SJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010, 102:39-46. 10.1093/jnci/djp404

25. Kim JH, Lee B, Han DH, Chung KL, Jeong JG, Chung BI: Discrepancies on the association between androgen deprivation therapy for prostate cancer and subsequent dementia: meta-analysis and meta-regression. Oncotarget. 2017, 8:73087-97. 10.18632/oncotarget.20391

26. Morgia G, Russo GI, Tubaro A, et al.: Prevalence of cardiovascular disease and osteoporosis during androgen deprivation therapy prescription discordant to EAU guidelines: results from a multicenter, cross-sectional analysis from the CHOIsing Treatment for Prostate cancer (CHOICE) study. Urology. 2016, 96:165-70. 10.1016/j.urology.2016.06.024

27. O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M: Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015, 33:1243-51. 10.1200/JCO.2014.59.1792

28. Oka R, Usami T, Endo T, et al.: Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int J Clin Oncol. 2016, 21:589-96. 10.1007/s10147-015-0891-7

29. Saigal CS, Gore IL, Krupski TL, Hanley I, Schonlau M, Litwin MS: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007, 110:1493-500. 10.1002/cncr.22953

30. Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, Ng CF: Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl. 2015, 17:495-6. 10.4103/1008-682X.145135

31. Van Hemelrijck M, Garmo H, Holmberg L, et al.: Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCaRsu Sweden. J Clin Oncol. 2010, 28:3448-56. 10.1200/JCO.2010.29.1567

32. Wallis CJ, Mahar AL, Satkunasivam R, et al.: Cardiovascular and skeletal-related events following localized prostate cancer treatment: role of surgery, radiotherapy, and androgen deprivation. Urology. 2016, 97:145-52. 10.1016/j.urology.2016.08.002

33. Nguyen C, Laxson DR, Swartz MD, Du XL: Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer. Pharmacotherapy. 2018, 38:999-1009. 10.1002/phar.21368

34. Graham AJ, Gelfand G, McFadden SD, Grondin SC: Levels of evidence and grades of recommendations in general thoracic surgery. Can J Surg. 2004, 47:461-5.

35. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn’t. BMJ. 1996, 312:71-2. 10.1136/bmj.312.7023.71